Strata Skin Sciences (NSDQ:SSKN) announced that it won FDA 510(k) clearance for its Xtrac Momentum excimer laser system for treating a number of skin diseases.

The Xtrac laser is designed to deliver a highly targeted therapeutic beam of UVB light in the treatment of psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma. It is made in three different platforms, with Ultra, Velocity and now Momentum to offer functionality and usability.

Strata’s Momentum platform’s clearance marks the first full platform clearance since Velocity won a nod in 2010, according to a news release. The latest version of the Xtrac laser, Momentum includes additional features such as an increased power range, a new proprietary short-hair tip for treating scalp psoriasis and an enhanced interface and database.

One of the last regulatory wins for the Xtrac system came in August 2018 when it won FDA 510(k) clearance for the Multi-Micro Dose tip designed for use with the Xtrac 308nm.

“Our R&D team is continually working to improve our systems and devices, and we are now beginning to see the fruits of that labor with our second 510(k) clearance in the last two years and first full Xtrac platform clearance since 2010,” Strata president & CEO Dr. Dolev Rafaeli said in the news release. “Strata and its Xtrac Excimer laser platforms dominate the dermatology global marketplace, further distancing Strata from other excimer platforms that have not improved their specifications in over 12 years. We look forward to additional advances and clearances as our team continues to expand the capabilities of this technology platform.”